These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27710135)

  • 1. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.
    Hurren KM; O'Neill JL
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1521-1526. PubMed ID: 27710135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.
    Dailey G; Lavernia F
    Diabetes Obes Metab; 2015 Dec; 17(12):1107-14. PubMed ID: 26139151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
    Owens DR
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New generation of insulins: glargine U300. Summary of clinical evidence].
    Musso C; Capurro L; Mingote E; Forti L; Guaita MS
    Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
    Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
    Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
    Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
    Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
    Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
    Danne T; Tamborlane WV; Malievsky OA; Franco DR; Kawamura T; Demissie M; Niemoeller E; Goyeau H; Wardecki M; Battelino T
    Diabetes Care; 2020 Jul; 43(7):1512-1519. PubMed ID: 32430458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Pettus J; Gill J; Paranjape S; Stewart J; Malla S; Edelman S; Bergenstal RM; Bode B
    Diabetes Obes Metab; 2019 Aug; 21(8):1906-1913. PubMed ID: 30993855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
    Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J; White JR
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study.
    Sawamura T; Karashima S; Ohbatake A; Higashitani T; Ohmori A; Sawada K; Yamamoto R; Kometani M; Katsuda Y; Yoneda T
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541176
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
    Oriot P; Jérémie W; Buysschaert M
    Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
    Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
    Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
    Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
    Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades.
    Saboo B; Chandalia H; Ghosh S; Kesavadev J; Kochar IPS; Prasannakumar KM; Sarda A; Bantwal G; Mehrotra RN; Rai M
    Curr Diabetes Rev; 2024; 20(1):e100323214554. PubMed ID: 36896906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
    Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.